Over 450 Total Lots Up For Auction at Three Locations - CO 05/12, PA 05/15, NY 05/20

Medtronic's OsteoCool RF Ablation System gets FDA expanded indication for palliative treatment of metastatic bone tumors

Press releases may be edited for formatting or style | February 15, 2017 Rad Oncology

The device also has a CE mark for the ablation of benign bone tumors such as osteoid osteoma and palliative treatment of metastatic malignant lesions involving bone, including the vertebral body. This indication is not available in the United States.


About Baylis Medical Company
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (U.K.) and Munich (Germany). For more information, visit www.baylismedical.com.


About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.


1 Gangi et al. Image-Guided Ablation Therapy of Bone Tumors. Elsevier Inc., 2009.
2 Schuleman et al. Economic Burden of Metastatic Bone Disease. American Cancer Society, 2007.
3 Nielson et al. Bone Metastases: Pathophysiology and Management Policy. American Society of Clinical Oncology, 1991.

Back to HCB News

You Must Be Logged In To Post A Comment